<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144606">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01895985</url>
  </required_header>
  <id_info>
    <org_study_id>849</org_study_id>
    <nct_id>NCT01895985</nct_id>
  </id_info>
  <brief_title>Efficacy of Latanoprostene Bunod in Lowering Intraocular Pressure in Japanese Healthy Male Volunteers</brief_title>
  <acronym>KRONUS</acronym>
  <official_title>A Single-Center, Open-Label Study Evaluating the Efficacy of Latanoprostene Bunod Ophthalmic Solution 0.024%, in Lowering Intraocular Pressure Over a 24-Hour Period in Japanese Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the effect of latanoprostene bunod dosed once
      daily (QD) in reducing intraocular pressure (IOP) measured over a 24-hour period in healthy
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>intraocular pressure (IOP)</measure>
    <time_frame>Visit 3 (Day 14/15)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Efficacy of latanoprostene bunod dosed QD in reducing IOP from baseline. IOP to be measured at multiple time points at visit 3.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood levels following a single dose</measure>
    <time_frame>12 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>The systemic pharmacokinetics (PK) of latanoprostene bunod, latanoprost acid, and Butanediol Mononitrate (BDMN) following a single dose of latanoprostene bunod. blood samples to be collected pre dose, and multiple time points over a 12 hour period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood levels following multiple dosing</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>The systemic PK of latanoprostene bunod, latanoprost acid and Butanediol Mononitrate (BDMN) following repeated QD dosing of latanoprostene bunod for 14 days. Blood samples to be collected prior to day 14 dose and at multiple time points following dosing over a 12 hour period.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Intraocular Pressure</condition>
  <arm_group>
    <arm_group_label>Latanoprostene Bunod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will instill 1 drop of latanoprostene bunod 0.024% topically into each eye QD in the evening for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprostene bunod</intervention_name>
    <arm_group_label>Latanoprostene Bunod</arm_group_label>
    <other_name>BOL-303259-X</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with a corrected decimal visual acuity (VA) of 0.5 or better in both
             eyes.

        Exclusion Criteria:

          -  Subjects with known hypersensitivity or contraindications to latanoprostene bunod, or
             any of the ingredients in the study drug.

          -  Subjects with known contraindications to NO treatment.

          -  Subjects who are unable to discontinue contact lens use at least 7 days prior to
             Visit 2 (Day 0/1/2) and during the 14 to 15-day study treatment period.

          -  Subjects who are unable to discontinue the use of all topical ophthalmic medications,
             including artificial tears, at least 7 days prior to Visit 2 (Day 0/1/2) and during
             the 14 to 15-day study treatment period.

          -  Subjects with any condition that prevents reliable applanation tonometry in either
             eye.

          -  Subjects with glaucoma in either eye.

          -  Subjects with any condition that prevents clear visualization of the fundus.

          -  Subjects who are monocular.

          -  Subjects with aphakia in either eye.

          -  Subjects with an active corneal disease in either eye.

          -  Subjects with severe dry eye in either eye.

          -  Subjects with a history/diagnosis of a clinically significant or progressive retinal
             disease in either eye.

          -  Subjects with any intraocular infection or inflammation within 3 months (90 days)
             prior to Visit 1 (Screening).

          -  Subjects with a history of ocular laser surgery within the 3 months (90 days) prior
             to Visit 1 (Screening).

          -  Subjects with a history of incisional ocular surgery or severe trauma.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Quintus Ngumah, OD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bausch &amp; Lomb Incorporated</name>
      <address>
        <city>Madison</city>
        <state>New Jersey</state>
        <zip>07940</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 26, 2013</lastchanged_date>
  <firstreceived_date>July 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
